{"id":205039,"name":"EXELIXIS","slug":"exelixis","state":"CA","country":"United States of America","description":"Genomics-based drug discovery company","totalSpending":1560000,"filings":27,"yearlySpending":[{"year":2020,"income":240000},{"year":2021,"income":240000},{"year":2022,"income":360000},{"year":2023,"income":240000},{"year":2024,"income":240000},{"year":2025,"income":240000}],"issues":["HCR","MMM"],"firms":["THORN RUN PARTNERS"],"lobbyists":["ANDREW ROSENBERG","GARY PALMQUIST","CATHERINE FINLEY","MICHAEL MCCARTHY"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Health & Human Services, Dept of (HHS)"],"sampleDescriptions":["Issues related to pharmaceutical pricing.","Issues related to the promotion of research and development.\nH.R. 6201, Families First Coronavirus Response Act;\nS. 3548, Coronavirus Aid, Relief, and Economic Security Act or the CARES Act.","Issues related to the promotion of research and development.","Issues related to the promotion of research and development.","Issues related to the promotion of research and development of prescription medications."],"years":[2020,2021,2022,2023,2024,2025]}